MARCY L’ETOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a global leader in the field of in vitro diagnostics, today announces the launch of VIDAS® B.R.A.H.M.S PCT. This new, CE approved test, was developed following the licensing agreement signed with B.R.A.H.M.S, enabling bioMérieux to develop, produce and market a test for measuring procalcitonin (PCT) levels. The test is sensitive and specific, used in the early detection of severe bacterial infections (e.g. sepsis).
